The Drug Company Settled. The Prescribers Did Not: What a $46 Million Federal Kickback Resolution Means for Florida Physicians and Specialty Pharmacies

A drug manufacturer resolved federal criminal and civil kickback allegations on August 10, 2026 for more than $46 million. It entered a deferred prosecution agreement, signed a five year corporate integrity agreement, and avoided a conviction. The physicians who accepted the dinners, the resort stays, and the consulting checks did not get that deal. Neither did the specialty pharmacies that took per patient payments dressed up as data services. Understand what actually happened here: the company bought its resolution by handing the government its expense reports, its internal emails, and access to its current and former employees.

A deferred prosecution agreement binds the government only as to the entity that signed it. The prescribers and pharmacies on the receiving end of the payments are a separate matter, and a later one.

Key Takeaways

• A manufacturer's deferred prosecution agreement resolves the company's exposure only. Prescribers and pharmacies remain separately liable under 42 U.S.C. § 1320a-7b(b).
• The Anti-Kickback Statute reaches both sides of a payment. Soliciting or receiving remuneration is a felony carrying up to ten years per count.
• Corporate cooperation credit is purchased with employee interviews and internal documents, which converts the company's records into the government's case against individuals.
• Underreported Open Payments data under 42 U.S.C. § 1320a-7h is now an investigative lead, not a compliance clerical issue.
• Florida's transplant programs and specialty pharmacies sit inside two of the most active federal healthcare fraud districts in the country.

What Actually Happened

A pharmaceutical manufacturer entered a deferred prosecution agreement in connection with a criminal information charging conspiracy to violate the federal Anti-Kickback Statute. The government alleged the company paid healthcare providers with lavish dinners, alcohol, gifts, resort stays, and consulting fees for work never performed, all to move prescriptions of one branded drug against a cheaper generic. The admitted conduct ran from late 2016 into mid 2023.

The terms: a criminal penalty above $10 million, a $34.45 million civil settlement under 31 U.S.C. § 3729, and a $1.55 million penalty for unreported physician payments under 42 U.S.C. § 1320a-7h.

Two facts there matter more to individual providers than the dollar figures. Company employees falsified expense reports, padding attendee lists to lower the apparent cost per head and omitting physician names to avoid Sunshine Act reporting. And the company earned cooperation credit by disclosing evidence the government did not have, facilitating interviews with current and former employees, and collecting material from third parties.

Employees padded attendee lists to lower the apparent cost per head and left physician names off to avoid Sunshine Act reporting. Those lists were reconstructed as part of the resolution.

Read those two facts together and the conclusion is straightforward. The reconstructed attendee lists exist, and the government has them.

What the Government Is Building Right Now

Corporate resolutions in healthcare fraud are rarely the end of an investigation. They are more often the midpoint. A company that wants a deferred prosecution agreement instead of a guilty plea has to deliver something, and what it delivers is individuals. Individual cases in this posture routinely get charged twelve to thirty six months after the company resolves.

Overlay Medicare Part D and Medicaid prescribing volume and you get a ranked list of prescribers whose ordering moved after the money started. That is the same data driven targeting behind the 2026 National Health Care Fraud Takedown and the continuing stream of HHS-OIG enforcement actions. Florida is squarely inside it. Last week the government resolved False Claims Act allegations against a Jacksonville based Medicare Advantage provider over false diagnosis coding.

"A company that wants a deferred prosecution agreement instead of a guilty plea has to deliver something, and what it delivers is individuals."— Aaron M. Cohen, AMC Defense Law

Exposure for Individual Providers and Pharmacies

The Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), runs both directions. Subsection (b)(2) criminalizes paying remuneration. Subsection (b)(1) criminalizes soliciting or receiving it. The manufacturer was charged on the paying side. Physicians and pharmacies that took the money are exposed on the receiving side, a felony carrying up to ten years and a $100,000 fine per violation. Remuneration is not limited to cash. Meals, travel, lodging, honoraria, and consulting fees all count.

The government also does not have to prove the payment was the only reason for a prescription. Under the one purpose rule, it is enough that one purpose was to induce referrals, even alongside legitimate ones.

Running parallel to all of it: treble damages under the False Claims Act, program exclusion under 42 U.S.C. § 1320a-7, state board discipline, and a qui tam complaint that may already be sealed on a docket.

The Mistakes That Turn a Subject Into a Defendant

Talking to agents without counsel. Two agents at your door are not there to hear your side. They are there to lock in statements they can later prove false. An imprecise answer about how many advisory boards you attended becomes a 18 U.S.C. § 1001 count that is far easier to prove than the kickback itself.

Assuming the company resolution closed the matter is the second mistake. The deferred prosecution agreement is the government's receipt for evidence it intends to use next.

Producing documents without a strategy is the third. A federal grand jury subpoena is not an administrative task for a practice manager. Scope, privilege, custodians, and litigation hold have to be handled deliberately, or you create obstruction exposure and surrender the only leverage a subject has, which is control over sequencing.

Fourth, calling the company's lawyers. Their client's interest in a cooperation posture is demonstrating that the misconduct belonged to individuals.

Retain independent federal investigation defense counsel. Fifth, and most common, waiting for the indictment. Pre-indictment defense is where these cases are decided.

What Effective Defense Looks Like at This Stage

Start by establishing where you sit. Witness, subject, and target are three postures with three strategies, and prosecutors will often tell defense counsel which applies when counsel knows how to ask. Then build the legitimacy record before the government builds the other one. These cases turn on whether services were actually rendered at fair market value. Calendars, drafts, decks, travel records, and contemporaneous notes either establish real work or they do not, and they land differently when counsel assembles and presents them than when an agent extracts them piecemeal.

Where the facts are bad, the work shifts to positioning. Volume of remuneration, absence of falsification, prompt remediation, and cooperation all carry real weight in charging decisions. A white collar defense attorney who puts that record in front of the line prosecutor before a charging memo moves up the chain is doing the highest value work available in a federal healthcare fraud matter.

Why the Next Several Months Matter

Charging decisions get made while the file is still open. Prosecutors have discretion over whom to charge, what to charge, and whether to resolve civilly instead of criminally, and they exercise it on incomplete information. That is precisely why information supplied by defense counsel moves outcomes.

The five year limitations period, measured from conduct that extended into 2023, gives the government room to work through a prescriber list without urgency. It does not give subjects the same room, because defense evidence degrades. Email systems purge. Employers change. A witness who remembers what was actually presented at an advisory board today will not in two years.

Common Questions

Facing a Federal Healthcare Fraud or Kickback Investigation in Florida?

AMC Defense Law represents physicians, pharmacy owners, executives, and healthcare businesses in federal investigations and prosecutions, including Anti-Kickback Statute and False Claims Act matters. If you have received a grand jury subpoena, a target letter, or an interview request, or you have reason to believe your arrangements are under review, the earliest stage is where counsel adds the most value. Consultations are confidential. The firm handles federal matters in the Southern and Middle Districts of Florida and nationwide.

The window that matters opens with the first subpoena or interview request and closes when the charging memo moves up the chain. That is the interval where counsel changes outcomes.

If you or your loved ones have been arrested or are facing a federal healthcare fraud investigation in Florida, call Aaron M. Cohen for a confidential consultation, 24 hours a day, to get help.

About the author: Aaron M. Cohen is the founder of AMC Defense Law, a federal and state criminal defense firm based in Boca Raton, Florida. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, white-collar crime, peptide and compounded-drug enforcement, financial crimes, and complex federal litigation, in Florida and nationwide.

This article is provided for general informational purposes only and does not constitute legal advice. Reading it does not create an attorney-client relationship with AMC Defense Law or with any of its attorneys. Every case turns on its own facts and no result is guaranteed. If you are the subject of a federal investigation, consult qualified counsel about your circumstances.